Innovation and Renovation: FEBS Open Bio in 2023
  Overview
        Overview
  Authors
          Authors
  Affiliations
        Affiliations
    Soon will be listed here.
  
  Abstract
            FEBS Open Bio is constantly evolving to best suit the needs of the scientific community. In this Editorial, we review the various new initiatives introduced in 2022 and look forward to the opportunities and challenges that lie ahead in 2023.
  References
                              1.
  
    Watts C
    
    . Lysosomes and lysosome-related organelles in immune responses. FEBS Open Bio. 2022; 12(4):678-693.
          PMC: 8972042.
    
          DOI: 10.1002/2211-5463.13388.
    
    View
  
2.
  
    Mion D, Bunel L, Heo P, Pincet F
    
    . The beginning and the end of SNARE-induced membrane fusion. FEBS Open Bio. 2022; 12(11):1958-1979.
          PMC: 9623537.
    
          DOI: 10.1002/2211-5463.13447.
    
    View
  
3.
  
    Rethi-Nagy Z, Abraham E, Lipinszki Z
    
    . GST-IVTT pull-down: a fast and versatile in vitro method for validating and mapping protein-protein interactions. FEBS Open Bio. 2022; 12(11):1988-1995.
          PMC: 9623517.
    
          DOI: 10.1002/2211-5463.13485.
    
    View
  
4.
  
    Caceres C, Seibert B, Cargnin Faccin F, Cardenas-Garcia S, Rajao D, Perez D
    
    . Influenza antivirals and animal models. FEBS Open Bio. 2022; 12(6):1142-1165.
          PMC: 9157400.
    
          DOI: 10.1002/2211-5463.13416.
    
    View
  
5.
  
    Qiao S, Zhang S, Ge J, Wang X
    
    . The spike glycoprotein of highly pathogenic human coronaviruses: structural insights for understanding infection, evolution and inhibition. FEBS Open Bio. 2022; 12(9):1602-1622.
          PMC: 9433818.
    
          DOI: 10.1002/2211-5463.13454.
    
    View